<mediadc-video-embed data-state="{"cms.site.owner":{"_ref":"00000161-3486-d333-a9e9-76c6fbf30000","_type":"00000161-3461-dd66-ab67-fd6b93390000"},"cms.content.publishDate":1657550390198,"cms.content.publishUser":{"_ref":"0000017b-3108-d928-a77f-73ccd2e60000","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"cms.content.updateDate":1657550390198,"cms.content.updateUser":{"_ref":"0000017b-3108-d928-a77f-73ccd2e60000","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"rawHtml":"
var _bp = _bp||[]; _bp.push({ "div": "Brid_57550381", "obj": {"id":"27789","width":"16","height":"9","video":"1049028"} }); ","_id":"00000181-eda6-ddeb-a5e1-fdbf3b8b0000","_type":"2f5a8339-a89a-3738-9cd2-3ddf0c8da574"}”>Video EmbedThe Food and Drug Administration will consider a French pharmaceutical company’s application to make its birth control medication available over the counter.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
Already a member? Log in
